Sign in Subscribe
Cardiology

Lipid-Lowering Agents Significantly Reduce Mortality Risk in Heart Disease Patients

Strategic Insights

— 1 min read

Researchers at the Department of Veterans Affairs Medical Center in Minneapolis conducted a retrospective cohort study to evaluate the effectiveness of lipid-lowering medication (LLM) on all-cause mortality in patients with known coronary heart disease. The study, published in the American Journal of Cardiology, analyzed data from 16,470 patients with CHD who were outpatients at one of five Veterans Affairs medical facilities in the upper Midwest between 1994 and 1996. The patients were followed until death or the end of the study in December 2000.

The study found that patients prescribed LLM had a significantly lower mortality rate compared to those not prescribed LLM. During an average follow-up of 5.9 years, there were 4,821 recorded deaths in patients not prescribed LLM (51%) and 1,245 deaths in patients prescribed LLM (18%). The treated cohort survived 15 months longer than the untreated group (p<0.001).

Key Takeaways:

  • Lipid-lowering agents significantly reduce the mortality risk for heart disease patients treated in a normal clinical environment.
  • Patients prescribed LLM had a significantly lower mortality rate compared to those not prescribed LLM (18% vs. 51%).
  • The treated cohort survived 15 months longer than the untreated group (p<0.001).
  • The study analyzed data from 16,470 patients with CHD who were outpatients at one of five Veterans Affairs medical facilities in the upper Midwest between 1994 and 1996.
  • The patients were followed until death or the end of the study in December 2000.
  • The study found that LLM was effective in reducing all-cause mortality in patients with established CHD.
  • The results of this study confirm the beneficial effects of LLM on total mortality in patients with established CHD.

Statistics:

  • 16,470 patients with CHD participated in the study (1994-1996)
  • 4,821 recorded deaths in patients not prescribed LLM (51%)
  • 1,245 deaths in patients prescribed LLM (18%)
  • Average follow-up time: 5.9 years
  • Hazard ratio for mortality in patients prescribed LLM: 0.34 (95% CI 0.32-0.36)
  • Survival time for patients prescribed LLM: 15 months (CI 14-16)

Sources:

  • Rubins, H.B. et al. (2003) Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs system. Am J Cardiol, 92(10), 1177-1182.
  • NewsRx.com & NewsRx.net (2003 DEC 29) Lipid-lowering agents significantly reduce mortality risk for heart disease patients.

Read more